Immunophage
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immunophage - overview
Established
2016
Location
Nanjing, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Nanjing, China, Nanjing and founded in 2016, Nanjing Immunophage Biomedical Co. ,Ltd, dba Immunophage, operates as a medical company that engages in developing drugs for the treatment of malignant tumors, autoimmune diseases, metabolic diseases and neurodegenerative diseases. The core team of the company is composed of former GSK executives. The company's founder, Dr.
Guohuang Fan, once managed the new drug R&D team at GSK China R&D Center. In 2018, it established the Shanghai R&D Center Amed Medical Technology (Shanghai) Co. , Ltd. Immunophage has subsidiaries in Australia and the United States.
In August 2025, Immunophage closed a venture funding from new investors Beijing New Medical Consulting, Zhoushan Hengkun Medical, Winfund Investment and returning investor Ennovation Ventures. The company's main business is the research and development of targeted drugs. In the field of oncology, it focuses on developing new immunomodulatory anti-tumor drugs to reverse the tumor immunosuppressive microenvironment. In the field of autoimmune diseases, metabolic diseases and neurodegenerative diseases, the company focuses on pathological changes caused by innate immune inflammation to develop new drugs.
The company generates revenue by developing medicines against cancer, autoimmune diseases, neurodegenerative disorders.
Current Investors
Yangtze River Capital, Nanjing Xinnong Capital, Ennovation Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.immunophage.com.cn
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Immunophage - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.